Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Published Date: 17 Sep 2026

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Pelvic RT Tied to Longer Survival in Cervical Cancer

Published Date: 17 Sep 2026

In patients with newly diagnosed stage IVB cervical cancer, adding definitive-dose pelvic radiotherapy to chemotherapy was associated with longer survival compared with chemotherapy alone.

New Data Put ADCs on the Map in Relapsed SCLC

Published Date: 17 Sep 2026

Two B7-H3-directed antibody-drug conjugates substantially improve survival over topotecan among patients with relapsed small cell lung cancer — pointing to a potential new treatment class.

Real-World Liso-Cel Results in MCL Consistent With Trials

Published Date: 17 Sep 2026

Two analyses of liso-cel CAR T-cell therapy in relapsed or refractory mantle cell lymphoma show response rates in the real-world setting similar to those seen in clinical trial populations.

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Published Date: 17 Sep 2026

Antibiotic use in patients under hospice care is associated with an increased risk for mortality; for infectious hospice-qualifying conditions, antibiotic use is linked to extended survival.

Knowledge Hub

Oncology

Prognosis of Cancer Dormancy Using Longitudinal Disease Signals

Comprehensive review of cancer dormancy prognosis using longitudinal disease signals for clinical practice.

Oncology

Tumor-Derived Exosomal Proteins and Cancer Progression

Comprehensive review of tumor-derived exosomal proteins and their impact on cancer progression for clinical practice.

Oncology

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Comprehensive review of screening and management strategies for cancer-treatment-related bone loss.

Oncology

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives

Comprehensive review of targeted protein degradation strategies in breast cancer, mechanisms, clinical impact, and future advances.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Pelvic RT Tied to Longer Survival in Cervical Cancer

New Data Put ADCs on the Map in Relapsed SCLC

Real-World Liso-Cel Results in MCL Consistent With Trials

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Knowledge Hub

Prognosis of Cancer Dormancy Using Longitudinal Disease Signals

Tumor-Derived Exosomal Proteins and Cancer Progression

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives

Oncology Drug Handling Near-Misses: Clinical Risks, Pathophysiology, and Guideline-Based Approaches

Molecular Glues for Solid Tumors: Mechanistic Insights, Clinical Relevance, and Therapeutic Potential

Therapeutic RNA Vaccines for Cancer: Mechanisms, Clinical Applications, and Future Directions

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Pelvic RT Tied to Longer Survival in Cervical Cancer

New Data Put ADCs on the Map in Relapsed SCLC

Real-World Liso-Cel Results in MCL Consistent With Trials

Antibiotic Use in Hospice Linked to Higher Mortality Risk

Knowledge Hub

Prognosis of Cancer Dormancy Using Longitudinal Disease Signals

Tumor-Derived Exosomal Proteins and Cancer Progression

Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Targeted Degradation in Breast Cancer: Mechanisms, Clinical Applications, and Future Perspectives

Oncology Drug Handling Near-Misses: Clinical Risks, Pathophysiology, and Guideline-Based Approaches

Molecular Glues for Solid Tumors: Mechanistic Insights, Clinical Relevance, and Therapeutic Potential

Therapeutic RNA Vaccines for Cancer: Mechanisms, Clinical Applications, and Future Directions

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views